ARS Pharmaceuticals's total assets for Q4 2025 were $327.65M, a decrease of -12.11% from the previous quarter. SPRY total liabilities were $213.39M for the fiscal quarter, a -5.22% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.